A diagnostic test for tuberculosis (TB) has a sensitivity of 95% and specificity of 98%. In a high-burden TB setting in Mumbai where the pre-test probability of active TB is 20%, a patient tests positive. Which of the following is the most appropriate next step?

Explanation

## Clinical Scenario Analysis A positive test for TB in a high-prevalence setting requires confirmation with microbiological evidence (sputum smear or GeneXpert MTB/RIF) before initiating anti-TB therapy. Although the test has excellent sensitivity (95%) and specificity (98%), the **positive predictive value (PPV)** must be calculated to understand the true probability of active TB. ### Post-Test Probability Calculation $$PPV = \frac{\text{Sensitivity} \times \text{Pre-test probability}}{(\text{Sensitivity} \times \text{Pre-test probability}) + ((1 - \text{Specificity}) \times (1 - \text{Pre-test probability}))}$$ $$PPV = \frac{0.95 \times 0.20}{(0.95 \times 0.20) + (0.02 \times 0.80)} = \frac{0.19}{0.19 + 0.016} = \frac{0.19}{0.206} ≈ 92\%$$ **Key Point:** Even with a PPV of ~92%, there is still an ~8% chance of false positivity. This is clinically significant because anti-TB therapy carries substantial toxicity (hepatotoxicity, peripheral neuropathy, drug interactions) and a 6-month course is burdensome. Microbiological confirmation is therefore mandatory. ## TB Diagnostic Algorithm (NAAT-Based Approach) ```mermaid flowchart TD A[Suspected TB: Positive screening test]:::outcome --> B{Microbiological confirmation available?}:::decision B -->|Yes: GeneXpert/Smear| C[Perform sputum examination]:::action C --> D{MTB detected?}:::decision D -->|Yes| E[Confirm active TB]:::outcome E --> F[Initiate anti-TB therapy]:::action D -->|No| G[Consider alternative diagnosis]:::outcome B -->|No| H[Clinical + radiological assessment]:::action H --> I{Highly suggestive of TB?}:::decision I -->|Yes| J[Initiate therapy + send sputum]:::action I -->|No| K[Further investigation]:::action ``` **High-Yield:** WHO and Indian TB guidelines mandate microbiological confirmation (sputum smear microscopy or GeneXpert MTB/RIF) before initiating anti-TB therapy in most settings. This is the **gold standard** and prevents unnecessary treatment of false positives. **Mnemonic: CONFIRM TB** — **C**linical suspicion + **O**ne positive test + **N**eed **F**or **I**nvestigation + **R**eliable **M**icrobiological confirmation + **T**hen **B**egin therapy. ## Why Microbiological Confirmation Is Essential 1. **High specificity of sputum smear/GeneXpert** — near 100% specificity for TB 2. **Reduces false positivity** — the 8% false positive rate from the screening test is eliminated 3. **Guides treatment intensity** — smear-positive (infectious) vs. smear-negative (non-infectious) affects contact tracing and isolation 4. **Prevents toxicity** — avoids exposing patients with false-positive results to 6 months of hepatotoxic drugs 5. **Guideline-mandated** — NTEP (National TB Elimination Programme) and WHO guidelines require microbiological confirmation